Immunocompromised patients can still receive convalescent plasma
United States to End Mpox Public Health Emergency in January
More than 29,000 Americans contracted the virus and 17 died during an outbreak that started earlier this year
Dynamically Updating Models Can Improve Prediction of COVID-19 Survival
Drift in model calibration performance was detected immediately, with minor fluctuations in discrimination
Study Looks at Extent of Residual Lung Abnormalities After COVID-19 Hospitalization
Posthospitalization prevalence of residual lung abnormalities estimated at 11.7 percent in sensitivity analyses
PTSD, Psychiatric Disorders Tied to Higher Risk for Severe COVID-19 Outcomes
Findings seen even when accounting for sociodemographic factors, comorbidities, and smoking
Poliovirus Investigation Integrates Michigan and Pennsylvania
During the summer of 2022, the state of New York (N.Y.) began investigating the presence of poliovirus in wastewater in various counties.
As of October 28, 2022, eight-two wastewater samples have been found genetically linked to the individual case of paralytic polio (Acute Flaccid Myelitis) in a Rockland County, N.Y., resident.
In response to the unknown risk, the U.S. Centers for Disease Control and Prevention (CDC) announced on November 30, 2022, that it would strategically expand poliovirus wastewater testing in select jurisdictions across the country.
Lyme Disease Vax Candidate Posts Positive Antibody Persistence Data
According to an announcement today, a Lyme disease vaccine candidate may soon obtain approval in the U.S. This would be significant since Lyme disease remains a serious health risk to most people.
This vector-borne illness is considered common in the Northern Hemisphere.
Each year, approximately 30,000 cases of Lyme disease are reported to U.S. CDC.
Earlier today, Pfizer Inc. and Valneva SE reported antibody persistence data six months after completing a three-dose or a two-dose vaccination schedule with their Lyme disease vaccine candidate.
Fewer Parents Talking to Child’s Regular Provider About Vaccines
Conversations less often about flu or COVID-19 vaccines versus school-required vaccines
Temporal Improvement Seen in Standard of Care for Hospitalized COVID-19 Patients
Outcomes improved from Adaptive COVID-19 Treatment Trial-2 to ACTT-3, although potential explanatory factors were similar
Overactive Bladder Common in Postacute COVID-19 Syndrome
COVID-19 may lead to new or worsening urinary symptoms in men and women